
Filippo Ansaldi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2592760/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. Journal of Medical Virology, 2005, 76, 327-332.	5.0	153
2	Hepatitis C virus in the new era: Perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World Journal of Gastroenterology, 2014, 20, 9633.	3.3	135
3	Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. Critical Care, 2019, 23, 219.	5.8	123
4	Cross-protection by MF59â,,¢-adjuvanted influenza vaccine: Neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine, 2008, 26, 1525-1529.	3.8	117
5	Clinical and Therapeutic Aspects of Candidemia: A Five Year Single Centre Study. PLoS ONE, 2015, 10, e0127534.	2.5	90
6	Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. Vaccine, 2010, 28, 4123-4129.	3.8	87
7	Novel Approach To Reduce the Hepatitis C Virus (HCV) Window Period: Clinical Evaluation of a New Enzyme-Linked Immunosorbent Assay for HCV Core Antigen. Journal of Clinical Microbiology, 2001, 39, 3110-3114.	3.9	86
8	Effectiveness of pneumococcal vaccines in preventing pneumonia in adults, a systematic review and meta-analyses of observational studies. PLoS ONE, 2017, 12, e0177985.	2.5	69
9	Characteristics of Staphylococcus aureus Bacteraemia and Predictors of Early and Late Mortality. PLoS ONE, 2017, 12, e0170236.	2.5	67
10	The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on hospitalization for pneumonia in children: A systematic review and meta-analysis. Vaccine, 2017, 35, 5776-5785.	3.8	56
11	Clinical characteristics and predictors of mortality in cirrhotic patients with candidemia and intra-abdominal candidiasis: a multicenter study. Intensive Care Medicine, 2017, 43, 509-518.	8.2	51
12	Global reaction to the recent outbreaks of Zika virus: Insights from a Big Data analysis. PLoS ONE, 2017, 12, e0185263.	2.5	51
13	Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid). Human Vaccines and Immunotherapeutics, 2016, 12, 1-18.	3.3	49
14	Evaluation of a new hepatitis C virus sequencing assay as a routine method for genotyping. Journal of Medical Virology, 2001, 63, 17-21.	5.0	43
15	Intradermal influenza vaccine and new devices: a promising chance for vaccine improvement. Expert Opinion on Biological Therapy, 2011, 11, 415-427.	3.1	40
16	Molecular and Serological Diversity of Neisseria meningitidis Carrier Strains Isolated from Italian Students Aged 14 to 22 Years. Journal of Clinical Microbiology, 2014, 52, 1901-1910.	3.9	40
17	Molecular characterization of influenza B viruses circulating in northern Italy during the 2001-2002 epidemic season. Journal of Medical Virology, 2003, 70, 463-469.	5.0	39
18	Fluzone® intra-dermal (Intanza®/Istivac® Intra-dermal): An updated overview. Human Vaccines and Immunotherapeutics, 2016, 12, 2616-2627.	3.3	37

FILIPPO ANSALDI

#	Article	IF	CITATIONS
19	Invasive Candida Infections in Liver Transplant Recipients: Clinical Features and Risk Factors for Mortality. Transplantation Direct, 2017, 3, e156.	1.6	34
20	Fluzone®Intradermal vaccine: a promising new chance to increase the acceptability of influenza vaccination in adults. Expert Review of Vaccines, 2012, 11, 17-25.	4.4	33
21	Changes in the hemagglutinins and neuraminidases of human influenza B viruses isolated in Italy during the 2001-02, 2002-03, and 2003-04 seasons. Journal of Medical Virology, 2004, 74, 629-640.	5.0	29
22	Intanza® 15mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses. Vaccine, 2012, 30, 2908-2913.	3.8	27
23	State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization. Journal of Immunology Research, 2016, 2016, 1-19.	2.2	26
24	Vaccine-preventable infections in Systemic Lupus Erythematosus. Human Vaccines and Immunotherapeutics, 2016, 12, 632-643.	3.3	26
25	Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: The importance of cross-protection. Vaccine, 2009, 27, 3345-3348.	3.8	25
26	Increasing Incidence of <i>Streptococcus pneumoniae</i> Serotype 19A and Emergence of Two Vaccine Escape Recombinant ST695 Strains in Liguria, Italy, 7 Years after Implementation of the 7-Valent Conjugated Vaccine. Vaccine Journal, 2011, 18, 343-345.	3.1	25
27	Carriage ofStreptoccoccus pneumoniaein healthy adults aged 60 years or over in a population with very high and long-lasting pneumococcal conjugate vaccine coverage in children. Human Vaccines and Immunotherapeutics, 2013, 9, 614-620.	3.3	25
28	Head-to-head comparison of an intradermal and a virosome influenza vaccine in patients over the age of 60. Human Vaccines and Immunotherapeutics, 2013, 9, 591-598.	3.3	25
29	New A/H3N2 Influenza Variant: a Small Genetic Evolution but a Heavy Burden on the Italian Population during the 2004-2005 Season. Journal of Clinical Microbiology, 2005, 43, 3027-3029.	3.9	24
30	Hepatitis A incidence and hospital-based seroprevalence in Italy: a nation-wide study. European Journal of Epidemiology, 2008, 23, 45-53.	5.7	23
31	Real-World Effectiveness and Safety of a Live-Attenuated Herpes Zoster Vaccine: A Comprehensive Review. Advances in Therapy, 2016, 33, 1094-1104.	2.9	22
32	The Molecular Epidemiology and Evolutionary Dynamics of Influenza B Virus in Two Italian Regions during 2010–2015: The Experience of Sicily and Liguria. International Journal of Molecular Sciences, 2016, 17, 549.	4.1	21
33	Fifteen years of epidemiologic, virologic and syndromic influenza surveillance: A focus on type B virus and the effects of vaccine mismatch in Liguria region, Italy. Human Vaccines and Immunotherapeutics, 2017, 13, 456-463.	3.3	21
34	Immunization Campaigns and Strategies against Human Papillomavirus in Italy: The Results of a Survey to Regional and Local Health Units Representatives. BioMed Research International, 2019, 2019, 1-8.	1.9	21
35	Molecular Characterization of a New Variant of Rotavirus P[8]G9 Predominant in a Sentinel-Based Survey in Central Italy. Journal of Clinical Microbiology, 2007, 45, 1011-1015.	3.9	19
36	Epidemiological changes after PCV7 implementation in Italy: Perspective for new vaccines. Hum Vaccin, 2011, 7, 211-216.	2.4	19

FILIPPO ANSALDI

#	Article	IF	CITATIONS
37	Pneumococcus and the Elderly in Italy: A Summary of Available Evidence Regarding Carriage, Clinical Burden of Lower Respiratory Tract Infections and On-Field Effectiveness of PCV13 Vaccination. International Journal of Molecular Sciences, 2016, 17, 1140.	4.1	19
38	Trends of influenza B during the 2010–2016 seasons in 2 regions of north and south Italy: The impact of the vaccine mismatch on influenza immunisation strategy. Human Vaccines and Immunotherapeutics, 2018, 14, 523-531.	3.3	19
39	Italian Health Care Workers' Knowledge, Attitudes, and Practices Regarding Human Papillomavirus Infection and Prevention. International Journal of Environmental Research and Public Health, 2020, 17, 5278.	2.6	19
40	Predictors of Mortality with Staphylococcus aureus Bacteremia in Elderly Adults. Journal of the American Geriatrics Society, 2018, 66, 1284-1289.	2.6	18
41	Carriage of Streptoccoccus pneumoniae 7 years after implementation of vaccination program in a population with very high and long-lasting coverage, Italy. Vaccine, 2012, 30, 2288-2294.	3.8	17
42	Latent Tuberculosis Infection among a Large Cohort of Medical Students at a Teaching Hospital in Italy. BioMed Research International, 2015, 2015, 1-6.	1.9	17
43	Universal influenza virus vaccines: what needs to happen next?. Expert Opinion on Biological Therapy, 2019, 19, 671-683.	3.1	17
44	Antigenic characterisation of influenza B virus with A new microneutralisation assay: Comparison to haemagglutination and sequence analysis. Journal of Medical Virology, 2004, 74, 141-146.	5.0	16
45	Burden and Prevention of HPV. Knowledge, Practices and Attitude Assessment Among Pre-Adolescents and their Parents in Italy. Current Pharmaceutical Design, 2020, 26, 326-342.	1.9	16
46	Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy. Pathogens, 2020, 9, 76.	2.8	14
47	Syndrome surveillance and molecular epidemiology for early detection and tracing of an outbreak of measles in Liguria, Italy. Journal of Medical Virology, 2009, 81, 1807-1813.	5.0	13
48	Neutralizing and Hemagglutination-Inhibiting Activities of Antibodies Elicited by the 2004-2005 Influenza Vaccine against Drifted Viruses. Vaccine Journal, 2006, 13, 162-164.	3.1	12
49	Analysis of a 3-months measles outbreak in western Liguria, Italy: Are hospital safe and healthcare workers reliable?. Journal of Infection and Public Health, 2020, 13, 619-624.	4.1	11
50	Burden of Rotavirus-Associated and Non-Rotavirus-Associated Diarrhea among Nonhospitalized Individuals in Central Italy: A 1-Year Sentinel-Based Epidemiological and Virological Surveillance. Clinical Infectious Diseases, 2008, 46, e51-e55.	5.8	10
51	Volatile Organic Compounds in Anatomical Pathology Wards: Comparative and Qualitative Assessment of Indoor Airborne Pollution. International Journal of Environmental Research and Public Health, 2017, 14, 609.	2.6	10
52	A comparison of coronavirus disease 2019 and seasonal influenza surveillance in five European countries: France, Germany, Italy, Spain and the United Kingdom. Influenza and Other Respiratory Viruses, 2022, 16, 417-428.	3.4	10
53	Potential effect of PCV13 introduction on Emergency Department accesses for lower respiratory tract infections in elderly and at risk adults. Human Vaccines and Immunotherapeutics, 2015, 11, 166-171.	3.3	9
54	Is first-line antimicrobial therapy still adequate to treat MRSA in the ICU? A report from a highly endemic country. Critical Care, 2016, 20, 246.	5.8	9

FILIPPO ANSALDI

#	Article	IF	CITATIONS
55	Alcohol and liver transplantation: the 6-month abstinence rule is not a dogma. Transplant International, 2016, 29, 953-954.	1.6	8
56	The Unknown Health Burden of Herpes Zoster Hospitalizations: The Effect on Chronic Disease Course in Adult Patients ≥50 Years. Vaccines, 2020, 8, 20.	4.4	8
57	ls empiric daptomycin effective in reducing mortality in Staphylococcus aureus bacteraemia? A real-life experience. Intensive Care Medicine, 2015, 41, 2026-2028.	8.2	6
58	Identification of key mutations in HIV reverse transcriptase gene can influence the clinical outcome of HAART. Journal of Medical Virology, 2001, 64, 199-206.	5.0	4
59	COVIDâ€19: Some clinical questions after the first 4Âmonths. European Journal of Clinical Investigation, 2020, 50, e13326.	3.4	4
60	Simultaneous Detection of Anti-HCV Antibody and HCV Core Antigen. Methods in Molecular Biology, 2009, 510, 15-23.	0.9	3
61	Economic burden of pneumococcal disease in children in Liguria, Italy. Human Vaccines and Immunotherapeutics, 2022, 18, .	3.3	3
62	The Authors' Reply. Drugs and Aging, 2011, 28, 505-507.	2.7	0
63	A comparative analysis of the first and second COVID-19 wave in Italy: evaluation of mortality in the Infectious Disease Unit of Genoa University Hospital New Microbiologica, 2021, 44, 245-247.	0.1	0